Skip to main content
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2013 Dec 14;19(46):8770–8779. doi: 10.3748/wjg.v19.i46.8770

Meta-analysis of Barrett’s esophagus in China

Ying Dong 1,2, Bing Qi 1,2, Xiao-Ying Feng 1,2, Chun-Meng Jiang 1,2
PMCID: PMC3870527  PMID: 24379599

Abstract

AIM: To investigate the epidemiology and characteristics of Barrett’s esophagus (BE) in China and compare with cases in the west.

METHODS: Studies were retrieved from the China National Knowledge Infrastructure and PubMed databases using the terms “Barrett” and “Barrett AND China”, respectively, as well as published studies about BE in China from 2000 to 2011. The researchers reviewed the titles and abstracts of all search results to determine whether or not the literature was relevant to the current topic of this research. The references listed in the studies were also searched. Inclusion and exclusion criteria for the literature were appropriately established, and the data reported in the selected studies were analyzed. Finally, a meta-analysis was performed.

RESULTS: The current research included 3873 cases of BE from 69 studies. The endoscopic detection rate of BE in China was 1%. The ratio of male to female cases was 1.781 to 1, and the average age of BE patients was 49.07 ± 5.09 years. Island-type and short-segment BE were the most common endoscopic manifestations, accounting for 4.48% and 80.3%, respectively, of all cases studied. Cardiac-type BE was observed in 40.0% of the cases, representing the most common histological characteristic of the condition. Cancer incidence was 1.418 per 1000 person-years.

CONCLUSION: Average age of BE patients in China is lower than in Western countries. Endoscopic detection and cancer incidence were also lower in China.

Keywords: Barrett’s esophagus, Epidemiology, Cancer incidence, China, Meta-analysis


Core tip: Barrett’s esophagus (BE) is a precursor of esophageal adenocarcinoma. Western countries have published more research on BE than China has. Thus, epidemiological knowledge of BE in China is inadequate. Diagnosis and treatment of BE in China is based on western criteria, therefore, diagnosis, monitoring, and treatment of BE require more data based on the unique characteristics of patients and clinics in China. The current research analyzed 69 clinical studies to obtain a comprehensive understanding of BE in China. Results provide important guidelines that can help improve the treatment and follow-up of BE patients in China.

INTRODUCTION

Barrett’s esophagus (BE) is a pathological phenomenon that occurs when the stratified squamous epithelium in the lower esophagus is replaced by a metaplastic simple columnar epithelium. In some cases, BE is accompanied by intestinal metaplasia, which is considered a precursor of esophageal adenocarcinoma[1]. Academics in Western countries have conducted more research on the subject than researchers in China. As such, despite the attention BE has drawn in recent years, epidemiological knowledge of BE in China is insufficient. The Digestive Disease Branch of the Chinese Medical Association drafted the Diagnosis and Treatment Consensus[2] of BE in 2005 and amended it in 2011, when a consensus amongst clinicians was finally achieved[1]. This consensus on BE, however, is based on western standards. Thus, the diagnosis, monitoring, and treatment of BE in China require more data based on Chinese clinics.

Although increasing numbers of researchers in China have focused on BE, the studies published thus far do not feature large samples or prospective designs. A systematic review[3] of the clinical characteristics of BE in China was published in 2008. However, in this review, studies that used metaplasia as a necessary standard were not excluded, which contradicts the consensus. In addition, the sample sizes of some included studies are rather small, with reports featuring only one or two cases. The present study aims to obtain a comprehensive understanding of the characteristics of BE in China by conducting a meta-analysis on BE in China and comparing findings with cases in Western countries. Results will help improve the treatment and follow-up of Chinese BE patients.

MATERIALS AND METHODS

Sources of literature and retrieval methods

Information from the China National Knowledge Infrastructure (CNKI) and PubMed databases were used. Clinical studies on BE published in Chinese between 2000 and 2011 were retrieved from the CNKI database, and those published in English were obtained from the PubMed database using the keywords “Barrett” and “Barrett AND China”, respectively. The researchers reviewed the titles and abstracts of all search results to determine whether or not the study was relevant to the current topic. The references listed in the studies obtained were also reviewed to locate additional studies.

Inclusion criteria of studies

The selected studies met the following criteria: (1) all of the cases described were from China; (2) diagnosis of BE conformed to standards set by the Digestive Disease Branch of the Chinese Medical Association in 2011; (3) BE was diagnosed through endoscopy and pathology; and (4) the number of cases included in the sample was > 10.

Exclusion criteria of studies

Studies were excluded if they featured any of the following criteria: (1) only published as an abstract; (2) intestinal metaplasia was used as a necessary diagnostic criteria; (3) the clinical aspects of BE were insufficient; that is, the study lacked at least three of the following aspects: endoscopic detection rate, sex, age, endoscopic manifestations, or histological type; (4) only a short segment of the study focused on BE; or (5) duplicate publication.

Data extraction and statistical analysis

Four researchers independently extracted data from every study, and any ensuing disagreements were resolved through discussion. The following data were extracted: name of the first author; year of publication; region of study; total number of cases; male to female ratio of the patients; average age, endoscopic detection rate; proportion of each endoscopic and histological type; follow-up cases and follow-up duration; and occurrence of esophageal adenocarcinoma during follow-up.

Data were analyzed using SPSS version 17.0. Proportions were evaluated using standard formulas. A mean difference demonstrating a 95% confidence rate was used for continuous data. The total number of person-years during follow-up was calculated by multiplying the number of follow-up cases with the follow-up duration. Cancer incidence was calculated by dividing the number of occurrences of esophageal adenocarcinoma among the follow-up cases by the total number of person-years.

RESULTS

Sources of studies

A total of 1121 studies were found in the CNKI database, and 108 of these studies met the inclusion criteria. Among these studies, 42 were rejected on the basis of the exclusion criteria; seven[4-10] for using intestinal metaplasia as a necessary diagnostic standard; 28[11-38] for having insufficient data on the clinical aspects of BE; four[39-42] for providing only a small study on BE; and one each for inconsistent data[43], doubts about plagiarism[44] and duplicate publication[45]. A total of 65 studies were found in the PubMed database; five of which met the inclusion criteria. Among these studies, one[46] was excluded because of its duplicate publication in Chinese, and another[47] was excluded for its use of intestinal metaplasia as a necessary diagnostic standard. A total of 69[48-116] studies were included in the present research. The screening process is summarized using the flow diagram shown in Figure 1.

Figure 1.

Figure 1

Flow diagram for the literature search. CNKI: China National Knowledge Infrastructure.

Characteristics of included studies

The 69 studies included in the present research were conducted in 25 provinces. The total number of samples in these studied was 12404, and the total number of cases was 3873 (Table 1).

Table 1.

Characteristics of the selected studies

Ref. Year of publication Region (province) Cases Male Female Mean age (yr)
Chen et al[48] 2011 Henan 150 60 90 45.42
Chen et al[49] 2011 Hubei 52 31 21 49
Guo et al[50] 2011 Hebei 42 27 15 48
Han et al[51] 2011 Jilin 30 21 9 45
Hao et al[52] 2011 Guangdong 76 58 18 50.6
Lin et al[53] 2011 Zhejiang 41 28 13 58.9
Lv et al[54] 2011 Zhejiang 108 80 28 61
Su et al[55] 2011 Hubei 23 13 10 40.3
Wang et al[56] 2011 Fujian 113 67 46 54.5
Zou et al[57] 2010 Guangxi 23 16 7 50.3
Xia et al[58] 2010 Hubei 56 34 22 45.85
Wu et al[59] 2010 Shanghai 84 50 34 36.3
Liu et al[60] 2010 Chongqing 62 35 27 51
Li et al[61] 2010 Anhui 32 18 14 48.6
Li et al[62] 2010 Guangdong 45 18 27 43
Hao et al[63] 2010 Henan 144 98 46 NA1
Yao et al[64] 2010 Sichuan 21 15 6 40.1
Tang et al[65] 2010 Jiangxi 63 43 20 45
Shi et al[66] 2010 Fujian 57 36 21 53
Jia et al[67] 2010 Shanxi 26 21 5 49
Gao et al[68] 2010 Hubei 32 21 11 NA
Tian et al[69] 2009 Shandong 59 43 16 49.14
Li et al[70] 2009 Guangxi 38 27 11 47.56
Dai et al[71] 2009 Hunan 23 18 5 50.3
Bai et al[72] 2009 Chongqing 67 41 26 50.7
Yang et al[73] 2009 Shaanxi 87 58 29 53.3
Yang et al[74] 2009 Ningxia 51 29 22 49.14
Tan et al[75] 2009 Liaoning 48 31 17 58.4
Qiu et al[76] 2009 Fujian 404 238 166 44.2
Lu et al[77] 2009 Jiangsu 12 9 3 NA
Liu et al[78] 2009 Liaoning 23 18 5 49
Gao et al[79] 2009 Liaoning 42 25 17 NA
Peng et al[80] 2009 Guangdong 27 14 13 48.18
Wu et al[81] 2008 Henan 25 16 9 48.3
Wang et al[82] 2008 Henan 12 10 2 49.5
Wang et al[83] 2008 Ningxia 109 64 45 50.11
Lu et al[84] 2008 Guangxi 32 22 10 52.5
Gao et al[85] 2008 Shandong 44 22 20 50
Zhang et al[86] 2008 Jiangxi 84 51 33 46
Yang et al[87] 2008 Hebei 74 40 34 52.6
Jian et al[88] 2008 Yunnan 68 51 17 52
Ji et al[89] 2008 Jiangsu 51 38 13 52.5
Tseng et al[90] 2008 Taiwan 12 9 3 61.6
Zhang et al[91] 2007 Shandong 30 24 6 52
Meng et al[92] 2007 Liaoning 21 13 8 54.6
Duan et al[93] 2007 Henan 54 38 16 51.6
Zhou et al[94] 2007 Zhejiang 13 7 6 NA
Wang et al[95] 2007 Hubei 88 61 27 47.46
Li et al[96] 2007 Fujian 75 45 30 45.42
Jin et al[97] 2007 Zhejiang 37 22 15 53
Zhou et al[98] 2006 Hubei 128 93 35 NA
Yang et al[99] 2006 Shaanxi 86 58 28 46
Wu et al[100] 2006 Fujian 13 10 3 48
Wang et al[101] 2006 Shaanxi 73 29 44 45.6
Suo et al[102] 2006 Fujian 37 24 13 50
Li et al[103] 2006 Liaoning 54 35 19 49
Li et al[104] 2006 Tianjin 37 25 12 58.3
Dou et al[105] 2006 Guizhou 89 57 32 46.3
Wang et al[106] 2006 Hubei 33 22 11 48
Shu et al[107] 2006 Hubei 13 12 1 NA
Zheng et al[108] 2005 Hubei 45 31 14 NA
Liang et al[109] 2005 Xinjiang 20 14 6 NA
Zhang et al[110] 2004 Shaanxi 69 54 15 56.2
Zhao et al[111] 2003 Shandong 55 38 17 46.8
Dong et al[112] 2003 Zhejiang 32 23 9 48.8
Zhang et al[113] 2001 Anhui 14 11 3 NA
Wang et al[114] 2001 Guangdong 21 16 5 67.3
Zhao et al[115] 2000 Shandong 35 26 9 NA
Yang et al[116] 2000 Beijing 29 22 7 50

NA: Not applicable (data were either unavailable or not reported).

Endoscopic detection rate

A total of 15 studies reported the endoscopic detection rate of BE, which was obtained from all patients who had undergone endoscopy. However, the detection rate varied significantly, with rates ranging from 0.06% to 17.65%. The total endoscopic detection rate was 1.0% (95%CI: 0.1%-1.8%).

Sex

All studies reported the sex of BE patients (Table 1). One study[85] was not included in this analysis because the sum of male and female patients was inconsistent with the reported total number of cases. The remaining 68 studies showed a total of 3829 cases with 2452 male patients, accounting for 64.0% of the sample (95%CI: 61.1%-67.0%), and 1377 female patients, accounting for 36.0% of the sample (95%CI: 33.0%-38.9%). The male to female ratio was 1.781 (95%CI: 1.552-2.009).

Age

A total of 58 studies reported the age of the BE patients (Table 1), and the average age of the patients was 49.07 ± 5.09 years.

Endoscopic manifestations

The endoscopic patterns of BE in 49 studies could be categorized into several types based on Herlihy criteria[117]: island, tongue, circumferential, and mixed. On the basis of the columnar epithelial length reported in 29 studies, BE was divided into long-segment BE (LSBE) (i.e., columnar epithelial metaplasia cells were involved in the entire circumference of the esophagus and the length of the segment was ≥ 3 cm) and short-segment BE (SSBE) (i.e., columnar epithelial metaplasia cells were not involved in the entire circumference of the esophagus or the whole circumference of esophagus was involved but the length of the segment was < 3 cm)[1] (Table 2).

Table 2.

Endoscopic manifestations of Barrett’s esophagus

Type Proportion 95%CI
Island 0.448  0.375-0.521
Tongue 0.262  0.204-0.320
Circumferential 0.247  0.190-0.303
Mixed 0.043 -0.006-0.093
SSBE 0.803  0.771-0.835
LSBE 0.197  0.165-0.229

The island type of Barrett’s esophagus (BE) accounted for 44.8% of all cases, the tongue type for 26.2%, the circumferential type for 24.7%, and the mixed type for 4.3%. Short-segment BE and long-segment BE accounted for 80.3% and 19.7% of the cases, respectively.

Histological type

The histological type of BE was divided into the gastric-fundic, cardiac, and intestinal metaplasia types[1] (Table 3).

Table 3.

Histological type of Barrett’s esophagus

Type Proportion 95%CI
Cardiac 0.400  0.310-0.491
Gastric-fundic 0.325  0.227-0.422
Intestinal Metaplasia 0.272  0.226-0.318
Mixed type 0.003 -0.002-0.008

The cardiac type accounted for 40.0% of the cases, the gastric-fundic type for 32.5%, the intestinal metaplasia type for 27.2%, and the mixed type for 0.3%.

Cancer incidence of BE

Thirty-one studies reported follow-up information. The total number of follow-up cases was 1283, with a follow-up duration ranging from 3 mo to 3 years. The mean follow-up duration was 1.099 years. Three studies[80,91,95] focused only on the follow-up of atypical hyperplasia of BE; thus, these studies were not included in this analysis. The total number of person-years during follow-up was 1410. Among 1283 cases, only two developed esophageal adenocarcinoma during the follow-up period; these cases were reported in two studies[91,103]. Four cases were also detected with esophageal adenocarcinoma during follow-up, but the number of follow-up cases and follow-up times were not provided. Studies with these cases were excluded from this analysis. The cancer incidence of BE was 1.418 per 1000 person-years.

DISCUSSION

The present research included 69 studies. The total endoscopic detection rate of BE was 1.0%, consistent with the total BE morbidity rate in Asia (0.9-1.2%) reported by Hou et al[118]. The endoscopic detection rate of BE in the reviewed studies ranged from 0.06% to 17.65%. Tseng et al[90] reported that the endoscopic detection rate of BE in Taiwan was 0.06%, which is much lower than the total detection rate observed in China. This variation may be attributed to their inclusion of upper gastrointestinal tract endoscopy in routine health maintenance programs, which can yield more reliable data on the prevalence of BE in local populations. The endoscopic detection rate of BE in most studies is based on patients who have undergone upper gastrointestinal tract endoscopy in a local hospital. These patients mainly suffer from several gastrointestinal symptoms such as regurgitation, heartburn, epigastric discomfort, nausea, vomiting, and eructation. Reports of such symptoms increase the detection rate of BE, so this result cannot represent the prevalence of BE in the general population.

In this research, the total endoscopic detection rate was lower than that reported in a meta-analysis in 2008[3] (2.39%), likely because of the increasing number of patients accepting endoscopy in recent years as a means of diagnosing and treating upper gastrointestinal tract diseases. Some patients opt to undergo endoscopic examination when experiencing upper gastrointestinal tract symptoms, while others choose endoscopy for routine health maintenance. Thus, the data do not provide sufficient evidence to conclude that the incidence of BE has declined in China.

The detection rate of BE in Western countries is 3%-8%[119], which is higher than that in China. Variations observed may be due to the following reasons: (1) variations in genetic and environmental factors; (2) western lifestyle and diet-related factors, such as visceral obesity, high-fat diet, and tobacco and alcohol consumption, which are risk factors for BE[118,120-133]; and (3) delayed recognition of BE in China, considering that current diagnostic standards are based on western practices and some Chinese doctors experience difficulties when diagnosing patients with BE.

In this research, the number of male BE patients was higher than that of female patients, which is similar to western reports[133]. The average age of onset of BE in this study was 49.07 years, whereas the average age in Western countries is 60 years[134,135]. Variations observed may be attributed to differences in the Chinese and western lifestyles.

The main types of endoscopic manifestations of BE include the island type and SSBE, which is similar to western reports[136]. Experts in the United States believe that LSBE and SSBE represent two different pathological changes and that the former is related to severe gastroesophageal reflux disease, which is common in older people. Although LSBE tends to increase the risk of cancer, no evidence today correlates the length of BE and cancer risk[137].

The number of cases of cardiac type BE was higher than that of other histological types in this research. Jankowski et al[138] reported that intestinal metaplasia progresses to cancer, and the Diagnosis and Treatment Consensus of BE of China (2011) regards intestinal metaplasia as a precursor of esophageal adenocarcinoma. Unfortunately, the reviewed studies present limited clinical and pathological data on intestinal metaplasia related to BE, considering Chinese researchers’ lack of knowledge on the topic. Some researchers believe that cancer formation is related to atypia of the epithelial instead of columnar epithelial metaplasia[139].

An individual with BE is estimated to be at 25-30 times greater risk of developing esophageal adenocarcinoma[140-143] than the general population. Cancer incidence was found to be 1.418 per 1000 person-years in the present study, which is lower than that in England (7.0 per 1000 person-years), United States (6.4 per 1000 person-years), and other European countries (5.6 per 1000 person-years)[144]. Thus, the cancer incidence of BE in China is lower than that in Western countries. The spectrum of BE characteristics differs significantly between the two regions.

COMMENTS

Background

Barrett’s esophagus (BE) is a precursor of esophageal adenocarcinoma. The Diagnosis and Treatment Consensus of BE in China is based on Western criteria. Epidemiological knowledge of BE in China is inadequate.

Research frontiers

A large number of clinical studies on BE have been conducted in China but they do not feature large sample sizes or prospective designs. A systematic review of the clinical characteristics of BE in China was published in 2008. However, in this review, studies that used metaplasia as a necessary standard were not excluded, which contrasts the consensus.

Innovations and breakthroughs

The Digestive Disease Branch of the Chinese Medical Association drafted the Diagnosis and Treatment Consensus of BE in 2005 and amended it in 2011, when a consensus amongst clinicians was achieved. Based on this consensus, the present research analyzed existing clinical studies with the aim of obtaining a comprehensive understanding of the characteristics of BE in China.

Applications

This research analyzed existing clinical studies with the aim of understanding the characteristics of BE in China. The results obtained will help improve the treatment and follow-up protocols of BE patients in China.

Terminology

BE is a pathological phenomenon that occurs when the stratified squamous epithelium in the lower esophagus is replaced by a metaplastic simple columnar epithelium. In some cases, BE is accompanied by intestinal metaplasia, which is considered a precursor of esophageal adenocarcinoma.

Peer review

This research has a high degree of significance. The meta-analysis presented here reviews the characteristics of the BE cases in China, including patient demographics, endoscopic and histological features, and risks for developing adenocarcinoma. The inclusion and exclusion criteria are appropriate, and the information obtained from selected reports is sufficiently analyzed.

Footnotes

P- Reviewers: Kastelein F, Sharma P S- Editor: Qi Y L- Editor: Kerr C E- Editor: Liu XM

References

  • 1.Digestive disease association, Chinese medical association. Diagnosis and Treatment Consensus of Barrett's Esophagus (June, 2011 Chongqing) Weichangbingxue He Ganbingxue Zazhi. 2011;29:1–2. [Google Scholar]
  • 2.Digestive disease association, Chinese medical association. Diagnosis and Treatment Consensus of Barrett's Esophagus (2005) Weichangbingxue He Ganbingxue Zazhi. 2006;15:80–81. [Google Scholar]
  • 3.Chen X, Zhu LR, Hou XH. Analysis of Clinical Characteristics of Chinese Barrett‘s Esophagus. Weichangbingxue He Ganbingxue Zazhi. 2008;17:102–105. [Google Scholar]
  • 4.Wu YF, Liu H, Li YX, Hu W, Zhou XL, Mao DH, Shi ZH. Clinical Observation of Argon Plasma Coagulation in Treatment of Barrett's Esophagus by Staining Magnifying Endoscopy. Neike Jiwei Zhongzheng Zazhi. 2009;15:154–155. [Google Scholar]
  • 5.Bai M, Liu ZH. Clinical Study of Argon Plasma Coagulation Combined with Omeprazole on Barrett's Esophagus. Chongqing Yixue Zazhi. 2009;38:415–416. [Google Scholar]
  • 6.Xiong LS, Cui Y, Wang JP, Wang JH, Xue L, Hu PJ, Chen MH. The Study of Diagnostic Criteria of Barrett's Esophagus. Zhongguo Xiaohua Neijing. 2008;2:33–36. [Google Scholar]
  • 7.Yu Y, Huang ZH, He GH. Endoscopic Finding and Clinical Analysis of Barrett's Esophagus. Nongken Yixue. 2006;28:152–153. [Google Scholar]
  • 8.Xue HB, Ge ZZ, Chen XY, Hu YB, Xiao SD, Mo JZ, Gao YJ, Song Y, Liu Y. Effect of Argon Plasma Coagulation on the Barrett's Esophagus. Zhonghua Xiaohua Neijing Zazhi. 2006;23:3–6. [Google Scholar]
  • 9.Wang Y, Liu XF. Discuss about Diagnosis of Barrett's Esophagus. Zhonghua Xiaohua Neijing Zazhi. 2003;20:339–340. [Google Scholar]
  • 10.Zhang J, Zhang SS, Luo JY, Gong J, Wang XQ, Zuo AL. Barrett's Esophagus: Clinical Study. Zhonghua Xiaohua Neijing Zazhi. 2001;18:15–18. [Google Scholar]
  • 11.Bao Y, Xia XH. Clinical Observation of Radio Frequency Combining Acid Suppression in Endoscopic Treatment of Barrett's Esophagus. Zhongguo Dangdai Yiyao Qikan. 2011;18:24–25. [Google Scholar]
  • 12.Jin GF, Tang Y. The Value of Narrow-band Imaging (NBI) in the Diagnosis of Barrett's Esophagus. Zhongguo Shequ Yishi. 2011;27:204. [Google Scholar]
  • 13.Ma AB. Study of Endoscopic Elastic Band in Treatment of Barrett's Esophagus. Yunnan Yiyao. 2011;32:496–497. [Google Scholar]
  • 14.Sun L, Qiu M, Xu R, Li X. 35 Cases of Barrett's Esophagus Clinical Pathology. Jilin Yiyao. 2011;32:7080–7081. [Google Scholar]
  • 15.Wen F, Zhu JL, Huang JZ, Qu L, Hu HT. Clinical Analysis of Argon Plasma Coagulation Combined with Rabeprazole for Barrett's Esophagus. Jujie Shoushu Zazhi. 2011;20:394–395. [Google Scholar]
  • 16.Wu HH, Zou HP, Du J. The Effective of Argon Plasma Coagulation for Treatment of Patients with Barrett's Esophagus. Wujing Yixueyuan Xuebao. 2011;20:213–214. [Google Scholar]
  • 17.Yan S. Clinical Study of Argon Plasma Coagulation Treatment of Barrett's Esophagus under Magnifying Endoscopy. Zhongguo Yiyao Zhinan. 2011;9:7–8. [Google Scholar]
  • 18.Zheng SJ, Zhang L, Zhang M, Yang LF. Argon Plasma Coagulation and Narrow Band Imaging Combined with Proton Pump Inhibitors in Diagnosis and Treatment of Barrett‘s Esophagus. Jiaotong Yixue. 2011;25:373–375. [Google Scholar]
  • 19.Zhong YF, Fan LH, Liu J. High Frequency Electrocoagulation Combined with Rabeprazole and Hydrotalcitum in Treatment of Island-type Barrett's Esophagus. Shiyong Yixue Zazhi. 2011;27:3176–3177. [Google Scholar]
  • 20.Htaj T, Zgl A. Prognosis Analysis of Argon Plasma Coagulation Combined with Proton Pump Inhibitors in Treatment of Barrett's Esophagus. Xinjiang Yiyao. 2010;40:13–16. [Google Scholar]
  • 21.Wang RL, Hou L, Yang WX, Gu P. Argon Plasma Coagulation Combined with Acid Suppression and Prokinetics in Treatment of Barrett's Esophagus. Xiandai Yixue Weisheng. 2010;26:3112. [Google Scholar]
  • 22.Liu ZX, Huang YX, Wen QS, Wang JJ, Zhao BM, Wang XX, Qin M, Zhao SG, Yang Q, Zhang SL. Clinical Analysis of Argon Plasma Coagulation in Treatment of Barrett's Esophagus in 118 Cases. Zhongguo Shiyong Zhenduan Zhiliao. 2010;24:53–54. [Google Scholar]
  • 23.Wang W, Liu HF, Wen XD, Wu QP. Prospective Study on Argon Plasma Coagulation Combined with Drugs for the Treatment of Barrett‘s Esophagus. Zhongguo Shiyong Zhenduan Zhiliao. 2009;23:538–540. [Google Scholar]
  • 24.Tang Y, Long XQ, Chen YJ, Yao Y. Clinical Study of Endoscopic Argon Plasma Coagulation and Acid Suppression for Treatment of Barret's Esophagus. Huaxi Yixue. 2009;24:664–665. [Google Scholar]
  • 25.Sheng JW, Fan HZ, Gao XH, Xie P. Radio Frequency Combined with Weifuchun in Treatment of Barret's Esophagus. Jiangxi Zhongyiyao Zazhi. 2009;8:27–28. [Google Scholar]
  • 26.Lv HY, Li ZW, Yao DH, He JT. Short-term Clinical Study of Argon Alasma Coagulation in Treatment of Barret's Esophagus in 23 Cases. Xinan Guofang Yixue. 2009;19:598–599. [Google Scholar]
  • 27.Lao YY, Chen Z. Endoscopic Argon Alasma Coagulation in Treatment of Barret's Esophagus in 23 Cases. Guangxi Yike Daxue Xuebao. 2009;26:808–809. [Google Scholar]
  • 28.Li HR, Mi CF, Cai YJ. High Frequency Electric Combining PPI, Anti-reflux and Mucosa-protection in Endoscopic Treatment of Barret’s Esophagus. Zhongguo Yiyao Zhinan. 2008;6:8–9. [Google Scholar]
  • 29.Chen W, Hang ZH, Zhou XG. Clinical Study of Argon Alasma Coagulation Combined with Rabeprazole in Treatment of Barret‘s Esophagus. Zhonghua Quanke Yixue. 2007;5:344–345. [Google Scholar]
  • 30.Li QX, Yin HK, Chen LJ. Effects of Esophageal Motility Abnormalities in Barret's Esophagus by Argon Alasma Coagulation Combined with Proton Pump Inhibitor. Zhongguo Yishi Jinxiu Zazhi. 2006;29:41–43. [Google Scholar]
  • 31.Zhao L, Wen JL, Wang WJ. Clinical Effect of Radio Frequency (RF) Combining Acid Suppression and Anti-reflux in Endoscopic Treatment of Barret‘s Esophagus (BE) Wannan Yixueyuan Xuebao. 2006;25:204–206. [Google Scholar]
  • 32.Liu YH, Yang XM, Wen ZW. Clinical Analysis of Argon Alasma Coagulation in Treatment of Barret‘s Esophagus in 16 Cases. Zhongguo Yishi Zazhi. 2006;8:1374–1375. [Google Scholar]
  • 33.Zhong DJ, Hao Y, Li XC, Zhou XM. Plasma Endothelin and Calcition in Gene-related Peptide in Barrett's Esophagus. Disi Junyi Daxue Xuebao. 2005;26:665–666. [Google Scholar]
  • 34.Zhu J, Huang JF, Bao BJ, Zhang XY. Clinical Effect of Argon Plasma Coagulation in Endoscopic Treatment of Barrett's Esophagus. Linchuang Huicui. 2005;20:541–543. [Google Scholar]
  • 35.Zhao M, Meng GX. Treatment of Barrett's Esophagus with Compound Ligation and Acid Suppression. Linchuang Yixue. 2005;25:1–2. [Google Scholar]
  • 36.Cui SZ, Zhang ZM, Hou ZB, Guo BM, Li XL. Clinical Experience about Diagnosis of Reflux Esophagitis and Barrett's Esophagus. Qinghai Yiyao Zazhi. 2004;34:55. [Google Scholar]
  • 37.Liu AL, He S, Zhang HY, Liu JH, Liu DW. Clinical Pathological Analysis of Barrett's Esophagus in 36 Cases. Zhonghua Xiaohua Neijing Zazhi. 2002;19:100–101. [Google Scholar]
  • 38.Fang DL, Ma ZS, Cheng QY, Yang HQ, Lv Y, Li ZH. Clinical Study on Reversal of Barrett's Esophagus with Acid Suppression and Microwave. Zhonghua Xiaohua Neijing Zazhi. 2001;8:207–209. [Google Scholar]
  • 39.Yuan S, Shu JC, Liu SX. Comparative Study of High Frequency Electrocoagulation versus Argon Plasma Coagulation in the Treatment of Short-segment Barrett's Esophagus. X. iandai Xiaohua Ji Jieru Zhiliao. 2009;14:77–79. [Google Scholar]
  • 40.OuYang JD, Gao J, Cheng LF. Endoscopic and Pathological Characteristics of Barrett's Esophagus. Zhongguo Weisheng Baojian Yiyao. 2008;10:35–37. [Google Scholar]
  • 41.Ding BJ, Xu Z. Clinical Effect of Radio Frequency in Treatment of Short-segment Barrett's Esophagus. Zhongguo Neijing Zazhi. 2006;12:1289–1290. [Google Scholar]
  • 42.Xu XR, Li ZZ, Zou DW, Xu GM, Sun ZX, Yin N. A Clinical Study of Short-segment Barrett's Esophagus. Zhonghua Xiaohua Zazhi. 2004;24:326–328. [Google Scholar]
  • 43.He M, Yang LL. Endoscopic Clinical Diagnosis and Pathological Characteristic Analysis of Barrett's Esophagus. Zhongguo Xiandai Yisheng. 2010;48:25–26. [Google Scholar]
  • 44.Qin GD, Zhang F. Analysis of Endoscopic and Clinical Features of Barrett's Esophagus. Changzhi Yixueyuan Xuebao. 2002;16:120–121. [Google Scholar]
  • 45.Chen T, Song WX, Wang HJ, Li DH. Analysis of Endoscopic Argon Alasma Coagulation Combined with Esomeprazole in Treatment of Barret‘s Esophagus. Xibao Fenzi Mianyixue Zazhi. 2011;27:227–228. [Google Scholar]
  • 46.Wang W, Zhang ZJ, Lin KR, Li DZ, Wen XD, Wu QP. The Prevalence, Clinical and Endoscopic Characteristics of Barrett‘s Esophagus in Fujian. Zhonghua Neike Zazhi. 2006;45:393–395. [PubMed] [Google Scholar]
  • 47.Xiong LS, Cui Y, Wang JP, Wang JH, Xue L, Hu PJ, Chen MH. Prevalence and risk factors of Barrett’s esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms. J Dig Dis. 2010;11:83–87. doi: 10.1111/j.1751-2980.2010.00419.x. [DOI] [PubMed] [Google Scholar]
  • 48.Chen CJ, You XD, Wang YQ. Clinical Analysis of Argon Alasma Coagulation Combined with Esomeprazole in Treatment of Barret's Esophagus in 100 Cases. Xiandai Xiaohua Jieru Zhiliao. 2011;16:55–57. [Google Scholar]
  • 49.Chen T, Song WX, Duan J. Early Therapeutic Observation on the Treatment of Barrett's Esophagus with Argon Plasma Coagulation Combined with Esomeprazole. Weichang Yixue. 2011;6:102–104. [Google Scholar]
  • 50.Guo HM, Cui BJ, Liu Y, Su B. Analysis of Barrett's Esophagus by Diagnosis of Endoscopy in 42 Cases. Zhongguo Wuzhenxue Zazhi. 2011;11:2959. [Google Scholar]
  • 51.Han YG, Lin Y. Clinical Symptom, Endoscopic Feature and Pothological Analysis of Barrett's Esophagus in 30 Cases. Zhongguo Shiyong Yiyao. 2011;6:102–103. [Google Scholar]
  • 52.Hao LP, Lai JY, Si HQ, Liu Q, Zhang XL, Lin YP, Gong FY. Clinical and Follow-up Analysis of Endoscopic Argon Alasma Coagulation Combined with Omeprazole of Barret's Esophagus in 30 Cases. Weichangbingxue Ji Ganbingxue Zazhi. 2011;20:429–431. [Google Scholar]
  • 53.Lin ZM. Clinical Analysis of Barret's Esophagus in 30 Cases. Zhongguo Zhongxiyi Jiehe Xiaohua Zazhi. 2011;19:178–179. [Google Scholar]
  • 54.Lv J, Ying Q. Endoscopic Analysis of Barret's Esophagus in 108 Cases. Zhongguo xiangcun Yiyao Zazhi. 2011;18:64. [Google Scholar]
  • 55.Su Y, Wu J, Wang P, Sun SB. Effect of Argon Plasma Coagulation on the Barrett’s Esophagus. Zhongguo Neijing Zazhi. 2011;17:53–56. [Google Scholar]
  • 56.Wang W, Liu HF, Li DZ, Zhang ZJ, Wen XD, Wu QP. Argon Plasma Coagulation Combined with Drugs for the Treatment of Barrett's Esophagus: a Prospective Study. Fuzhou Zhongyiyuan Xuebao. 2011;18:85–87. [Google Scholar]
  • 57.Zou YB, Rao GH, Wer SL. Endoscopic Argon Plasma Coagulation Combined with Rabeprazole in Treatment of Barret‘s Esophagus. Hainan Yixue. 2010;21:60–61. [Google Scholar]
  • 58.Xia YN, Luo HS, Li WS, Jiang HW, Huang CY, Tan P. The Clinical Effect of Argon Plasma Coagulation in Endoscopic Treatment of Barrett's Esophagus. Weichangbingxue He Ganbingxue Zazhi. 2010;19:459–461. [Google Scholar]
  • 59.Wu WC, Xu Lm, Zhang L, Zhou M, Qv CY, Zhang Y, Chen Y. Comparative Study of Two Different Treatment Methods on Barrett's Esophagus. Weichangbingxue He Ganbingxue Zazhi. 2010;1:818–820. [Google Scholar]
  • 60.Liu BL, Wang J, Wang JH. Effects of Argon Plasma Coagulation under Endoscopic on Barrett‘s Esophagus. Chongqing Yixue. 2010;39:2342–2343. [Google Scholar]
  • 61.Li X, Wang ZH, Yang SF, Shi ZW, He Y, Xiao Q, Dai DZ, Bao DM. Clinical Observation of Radio-frequency Ablation (RFA) Combined with Esomeprazole Magnesium and Almagate Suspension in Treatment of 32 Cases of Barrett's Esophagus (BE) Anhui Yixue. 2010;31:1491–1493. [Google Scholar]
  • 62.Li JS. Endoscopic Argon Plasma Coagulation in the Treatment of 45 Cases of Barrett's Esophagus. Xiandai Yiyuan. 2010;10:45–46. [Google Scholar]
  • 63.Hao RC, Fang P, Feng LX, Song SJ, Liang J. Experience on the Endoscopic Diagnosis of Barrett's Esophagus in 144 Cases. Wujing Yixueyuan Xuebao. 2010;19:816–817. [Google Scholar]
  • 64.Yao Y, Xu JY, Long XQ. Endoscopic Argon Plasma Coagulation for Barrett’s Esophagus: A Clinical Observation. Xinan Junyi. 2010;12:1057–1058. [Google Scholar]
  • 65.Tang SL, Shi QH. Endoscopic and Clinical Analysis of Barrett's Esophagus in 63 Cases. Shiyong Linchang Yixue. 2010;11:29–30. [Google Scholar]
  • 66.Shi H, Jiang SJ, Wang YG, Zhou D, Chen G, Cai H. Band Ligation-assisted Endoscopic Mucosal Resection for Barrett's Esophagus Killing Two Birds with One Stone. Zhonghua Linchuang Yishi Zazhi. 2010;4:410–413. [Google Scholar]
  • 67.Jia YM, Zhang AZ. Clinical Endoscopic and Pathological Analysis of Barrett's Esophagus in 26 Cases. Changzhi Yixueyuan Xuebao. 2010;24:366–367. [Google Scholar]
  • 68.Gao S, Chen X, Ding XW, Xu DQ, Chen XJ, Wang HX. Effects of Argon Plasma Coagulation Combined with Proton Pump Inhibitor on Barrett's Esophagus in 32 Cases. Zhonghua Shiyong Zhenduan Yu Zhiliao. 2008;22:726–728. [Google Scholar]
  • 69.Tian Y, Li YQ. The Relationship of Pathology and Clinical, Endoscopic Characteristics in Barrett's Esophagus. Weichangbingxue He Ganbingxue Zazhi. 2009;18:728–731. [Google Scholar]
  • 70.Li HQ, Bei GM, Yu TZ, Zhou Y, Zhang B, Zhang DQ. Clinical Observation of Argon Alasma Coagulation Combined with Plum Soup in Treatment of Barret's Esophagus. Sichan Zhongyi. 2009;27:69–71. [Google Scholar]
  • 71.Dai J, Tang JX, Xie N, Xiong XL, Liu CY. Clinical Observation of Argon Plasma Coagulation or Radio Frequency Combining Acid Suppression in Endoscopic Treatment of Barrett's Esophagus. Linchuang Huicui. 2009;24:120–122. [Google Scholar]
  • 72.Bai JY, Wang YQ, Zhao XY. Effect of Argon Plasma Coagulation on the Barrett's Esophagus. Jujie Shoushuxue Zazhi. 2009;18:165–166. [Google Scholar]
  • 73.Yang Q, Wang JJ, Yang Y. Clinical Study of Argon Plasma Coagulation Treatment of Barrett's Esophagus Under Endoscopy. Weichangbingxue He Ganbingxue Zazhi. 2009;18:355–356. [Google Scholar]
  • 74.Yang XM, Zhao CJ, Yu YH, Wang Y, Zhao J, Shen H, Hu SJ. Relationship Among Endoscopic Characteristics, Clinical Features and Pathologic Epithelial Types of Barrett's Esophagus. Ningxia Yixue Zazhi. 2009;31:605–606. [Google Scholar]
  • 75.Tan JX. Clinical Experience of Argon Plasma Coagulation in Treatment of Barrett's Esophagus. Zhongguo Yiyao Zhinan. 2009;7:30–31. [Google Scholar]
  • 76.Qiu QW, Lin CZ. Analysis on 404 Cases of Barrett's Esophagus. Xiandai Zhenduan Yu Zhliao. 2009;20:123–124. [Google Scholar]
  • 77.Lu W, Zhang W. Effect of Argon Plasma Coagulation on the Barrett's Esophagus. Binzhou Yixueyuan Xuebao. 2009;32:44–46. [Google Scholar]
  • 78.Liu XY, Zhang J. Clinical Analysis of 23 Cases of Barrett's Esophagus. Hebei Yixue. 2009;15:503–504. [Google Scholar]
  • 79.Gao N, Wang CX, Liu MH, Wang MC. Correlation Between Magnifying Chromoendoscopic Classification and Histological Type of Barrett‘s Esophagus: a Clinical Study. Zhonguo Yike Daxue Xuebao. 2009;38:465–467. [Google Scholar]
  • 80.Peng S, Cui Y, Xiao YL, Xiong LS, Hu PJ, Li CJ, Chen MH. Prevalence of erosive esophagitis and Barrett’s esophagus in the adult Chinese population. Endoscopy. 2009;41:1011–1017. doi: 10.1055/s-0029-1215291. [DOI] [PubMed] [Google Scholar]
  • 81.Wu YW, Guo XK. Endoscopic Argon Alasma Coagulation Combined with Acid Suppression in Treatment of Barret's Esophagus. Shiyong Yiyao Zazhi. 2008;25:424. [Google Scholar]
  • 82.Wang ZN. Clinical Observation of Esomeprazole Combined with Domperidone in Treatment of 12 Cases of Barret's Esophagus. Linchuang He Shiyan Yixue Zazhi. 2008;7:77. [Google Scholar]
  • 83.Wang QH, Guo XN. Clinical Research of Barrett's Esophagus. Ningxia Yixue. 2008;30:202–204. [Google Scholar]
  • 84.Lu Q. Clinical and Pathological Analysis of Barrett's Esophagus. Shiyong Zhenduan yu Zhiliao Zazhi. 2008;22:100–102. [Google Scholar]
  • 85.Gao J, OuYang JD, Zhao ZD, Zhang XY. Analysis Endoscopic and Pathological Characteristics of Barrett's Esophagus. Xiandai Yixue. 2008;36:290–292. [Google Scholar]
  • 86.Zhang C, Shi QH. Endoscopic and Pathological Analysis of 84 Cases of Barrett's Esophagus. Shiyong Linchuang Yixue. 2008;9:35–36. [Google Scholar]
  • 87.Yang J, Zhao J. Analysis of Endoscopic and Pathological Characteristics of 74 Cases of Barrett's Esophagus. Zhongguo Wuzhenxue Zazhi. 2008;8:5440–5441. [Google Scholar]
  • 88.Jian MS. Endoscopic Diagnosis of Barrett's Esophagus. Yunnan Yiyao. 2008;29:355. [Google Scholar]
  • 89.Ji G, Yan ZP, Chen J, Wang XQ, Yu WZ, Tai SL. Clinical Observation of Endoscopic in Treatment of Barret's Esophagus. Linchuang Huicui. 2008;23:880–881. [Google Scholar]
  • 90.Tseng PH, Lee YC, Chiu HM, Huang SP, Liao WC, Chen CC, Wang HP, Wu MS, Lin JT. Prevalence and clinical characteristics of Barrett’s esophagus in a Chinese general population. J Clin Gastroenterol. 2008;42:1074–1079. doi: 10.1097/MCG.0b013e31809e7126. [DOI] [PubMed] [Google Scholar]
  • 91.Zhang ZQ, Xu XJ. Clinical Analysis of 30 Cases of Barrett's Esophagus. Gongqi Yikan. 2007;20:26–27. [Google Scholar]
  • 92.Meng XG, Wang ZY, Zhu DM. Analysis of 21 Cases of Barrett‘s Esophagus. Zhongguo Wuzhenxue Zazhi. 2007;7:605–606. [Google Scholar]
  • 93.Duan SF, Gao CG. Analysis of Clinical Endoscopic and Pathological 54 Cases of Barrett's Esophagus. Zhongguo Wuzhenxue Zazhi. 2007;7:1072–1073. [Google Scholar]
  • 94.Zhou XB, Ye LP, Ding JX, Lin MH. Clinical Observation of Endoscopic Argon Alasma Coagulation in Treatment of Barret's Esophagus in 13 Cases. Xinyixue. 2007;38:749–750. [Google Scholar]
  • 95.Wang DR, Xu JY, Hou XH. The Clinical and Pathological Analysis of Barrett‘s Esophagus. Linchuang Xiaohuabing Zazhi. 2007;19:306–308. [Google Scholar]
  • 96.Li DZ, Wang W, Zhang ZJ, Lin KR, Zhu JZ, Wen XD. Effect of Different Treatments on Barrett's Esophagus. Shandong Yiyao. 2007;47:16–18. [Google Scholar]
  • 97.Jin ZC, Cai MY, Nie MW, Chen WX. Short-term Observation of Endoscopic Argon Alasma Coagulation in Treatment of Barret‘s Esophagus. Linchuang Yixue. 2007;27:42–43. [Google Scholar]
  • 98.Zhou J, Shen ZY, Luo HS, Shen L, Liu J, Yang YM, Zou LP. Comparisons of Endoscopic and Pathological Characteristics Between Long and Short Segment Barret’s Esophagus. Zhonghua Xiaohua Zazhi. 2006;26:440–443. [Google Scholar]
  • 99.Yang HY, Lei JK, Zhang MG, Han CL, Lu JX, Shi GM. Clinical Study of Barrett's Esophagus (BE) Xiandai Linchuang Yixue. 2006;32:168–170. [Google Scholar]
  • 100.Wu YL. Clinical Analysis of 13 Cases of Barrett's Esophagus. Xiandai Xiaohua Ji Jieru Zhiliao. 2006;11:40–41. [Google Scholar]
  • 101.Wang SL, Zhou Y, Ge FL. Clinical Analysis of Endoscopic Radio Frequency in Treatment of Barret's Esophagus in 73 Cases. Xibei Guofang Yixue Zazhi. 2006;27:138–139. [Google Scholar]
  • 102.Suo B, Su PL. Analysis of Clinical and Endoscopic Characteristics of Barrett's Esophagus. Zhonghua Xiaohua Neijing Zazhi. 2006;23:291–292. [Google Scholar]
  • 103.Li RK, Jiang CM. Clinical Analysis of 54 Cases of Barrett's Esophagus. Zhonghua Quanke Yishi Zazhi. 2006;5:304–306. [Google Scholar]
  • 104.Li FL, Hu JZ, Han YS. Clinical Analysis of Barrett’s Esophagus in 37 Cases. Zhongguo Neijin Zazhi. 2006;12:1172–1173. [Google Scholar]
  • 105.Dou XL, Chen WW, Du HT. Analysis of Endoscopic and Pathological Characteristics of Barrett’s Esophagus. Guizhou Yiyao. 2006;30:1011–1012. [Google Scholar]
  • 106.Wang P, He XF. Clinical Analysis of 33 Cases of Endoscopic Barrett's Esophagus. Xianning Xueyuan Xuebao. 2006;20:132. [Google Scholar]
  • 107.Shu Z. Stusy of Omeprazole in Treatment of Barret's Esophagus in 13 Cases. Linchuang He Shiyan Yixue Zazhi. 2006;5:915. [Google Scholar]
  • 108.Zheng LD, Yang XP, Liu JS, Hou XH. Clinical Pathological Characteristics of Barrett’s Esophagus. Zhonghua Xiaohua Zazhi. 2005;25:496–497. [Google Scholar]
  • 109.Liang Y. Clinical Analysis of 20 Cases of Barrett's Esophagus. Nongken Yixue. 2005;27:193–194. [Google Scholar]
  • 110.Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Barrett’s esophagus and its correlation with gastroesophageal reflux in Chinese. World J Gastroenterol. 2004;10:1065–1068. doi: 10.3748/wjg.v10.i7.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Zhao WD, Zhang WQ, Cui ZQ, Niu HZ. Analysis of Clinical, Endoscopic Characteristics and HP Detection Rate of 55 Cases of Barrett's Esophagus. Linchuang Neike Zazhi. 2003;20:305. [Google Scholar]
  • 112.Dong LH, Chen LG, Wang WY. Link of Barrett‘s Esophagus and Helicobacter Pylori Infection. Yishi Jinxiu Zazhi. 2003;26:24–25. [Google Scholar]
  • 113.Zhang GM. Clinical Analysis of 14 Cases of Barrett's Esophagus. Zhongguo Yejin Gongye Yixue Zazhi. 2001;18:211–212. [Google Scholar]
  • 114.Wang YM, Xu HL, Xiong YM, Zheng GR. Endoscopic and Clinical Analysis of Barrett's Esophagus. Zhonghua Xiaohua Neijing Zazhi. 2001;18:363–364. [Google Scholar]
  • 115.Zhao WD, Zhang WQ, Niu HZ, Niu Q. Analysis of Endoscopic Shape and HP Detection of 35 Cases of Barrett's Esophagus. Binzhou Yixueyuan Xuebao. 2000;23:349–350. [Google Scholar]
  • 116.Yang HY, Zhang MG, Zhao HC. Analysis of 29 Patients with Barrett's Esophagus. Zhongri Youhao Yiyuan Xuebao. 2000;14:33–35. [Google Scholar]
  • 117.Herlihy KJ, Orlando RC, Bryson JC, Bozymski EM, Carney CN, Powell DW. Barrett’s esophagus: clinical, endoscopic, histologic, manometric, and electrical potential difference characteristics. Gastroenterology. 1984;86:436–443. [PubMed] [Google Scholar]
  • 118.Hou XH, Zheng LD, Wang DR. Pathogeny and Epidemiology of Barrett‘s Esophagus. Zhonghua Xiaohua Zazhi. 2006;26:114–115. [Google Scholar]
  • 119.Casson AG, Williams L, Guernsey DL. Epidemiology and molecular biology of Barrett esophagus. Semin Thorac Cardiovasc Surg. 2005;17:284–291. doi: 10.1053/j.semtcvs.2005.09.005. [DOI] [PubMed] [Google Scholar]
  • 120.Fujiwara Y, Higuchi K, Watanabe Y, Shiba M, Watanabe T, Tominaga K, Oshitani N, Matsumoto T, Nishikawa H, Arakawa T. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol. 2005;20:26–29. doi: 10.1111/j.1440-1746.2004.03521.x. [DOI] [PubMed] [Google Scholar]
  • 121.Kuo CJ, Lin CH, Liu NJ, Wu RC, Tang JH, Cheng CL. Frequency and risk factors for Barrett’s esophagus in Taiwanese patients: a prospective study in a tertiary referral center. Dig Dis Sci. 2010;55:1337–1343. doi: 10.1007/s10620-009-0872-7. [DOI] [PubMed] [Google Scholar]
  • 122.Park JJ, Kim JW, Kim HJ, Chung MG, Park SM, Baik GH, Nah BK, Nam SY, Seo KS, Ko BS, et al. The prevalence of and risk factors for Barrett’s esophagus in a Korean population: A nationwide multicenter prospective study. J Clin Gastroenterol. 2009;43:907–914. doi: 10.1097/MCG.0b013e318196bd11. [DOI] [PubMed] [Google Scholar]
  • 123.Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol. 2006;4:398–407. doi: 10.1016/j.cgh.2005.10.011. [DOI] [PubMed] [Google Scholar]
  • 124.Wu JC. Gastroesophageal reflux disease: an Asian perspective. J Gastroenterol Hepatol. 2008;23:1785–1793. doi: 10.1111/j.1440-1746.2008.05684.x. [DOI] [PubMed] [Google Scholar]
  • 125.Ma XQ, Cao Y, Wang R, Yan X, Zhao Y, Zou D, Wallander MA, Johansson S, Liu W, Gu Z, et al. Prevalence of, and factors associated with, gastroesophageal reflux disease: a population-based study in Shanghai, China. Dis Esophagus. 2009;22:317–322. doi: 10.1111/j.1442-2050.2008.00904.x. [DOI] [PubMed] [Google Scholar]
  • 126.Lagergren J. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol. 2006;20:803–812. doi: 10.1016/j.bpg.2006.04.009. [DOI] [PubMed] [Google Scholar]
  • 127.Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344–1353. doi: 10.1093/jnci/djq289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett’s esophagus. Am J Gastroenterol. 2008;103:292–300. doi: 10.1111/j.1572-0241.2007.01621.x. [DOI] [PubMed] [Google Scholar]
  • 129.Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Quesenberry C, Rumore GJ, Buffler PA. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41; quiz 311. doi: 10.1053/j.gastro.2007.04.046. [DOI] [PubMed] [Google Scholar]
  • 130.Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162:1050–1061. doi: 10.1093/aje/kwi325. [DOI] [PubMed] [Google Scholar]
  • 131.Kubo A, Levin TR, Block G, Rumore G, Quesenberry CP, Buffler P, Corley DA. Cigarette smoking and the risk of Barrett’s esophagus. Cancer Causes Control. 2009;20:303–311. doi: 10.1007/s10552-008-9244-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Kubo A, Block G, Quesenberry CP, Buffler P, Corley DA. Effects of dietary fiber, fats, and meat intakes on the risk of Barrett’s esophagus. Nutr Cancer. 2009;61:607–616. doi: 10.1080/01635580902846585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Cameron AJ, Lomboy CT. Barrett’s esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992;103:1241–1245. doi: 10.1016/0016-5085(92)91510-b. [DOI] [PubMed] [Google Scholar]
  • 134.Caygill CP, Watson A, Reed PI, Hill MJ. Characteristics and regional variations of patients with Barrett’s oesophagus in the UK. Eur J Gastroenterol Hepatol. 2003;15:1217–1222. doi: 10.1097/00042737-200311000-00011. [DOI] [PubMed] [Google Scholar]
  • 135.Falk GW. Barrett’s esophagus. Gastroenterology. 2002;122:1569–1591. doi: 10.1053/gast.2002.33427. [DOI] [PubMed] [Google Scholar]
  • 136.Csendes A, Smok G, Quiroz J, Burdiles P, Rojas J, Castro C, Henríquez A. Clinical, endoscopic, and functional studies in 408 patients with Barrett’s esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol. 2002;97:554–560. doi: 10.1111/j.1572-0241.2002.05529.x. [DOI] [PubMed] [Google Scholar]
  • 137.Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330. doi: 10.1053/j.gastro.2004.04.010. [DOI] [PubMed] [Google Scholar]
  • 138.Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154:965–973. doi: 10.1016/S0002-9440(10)65346-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139.Zhang YL. Endoscopic Biopsy Diagnosis of Barrett's Esophagus. Zhonghua Xiaohua Neijing Zazhi. 2006;23:69–71. [Google Scholar]
  • 140.Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut. 2004;53:1070–1074. doi: 10.1136/gut.2003.028076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Cossentino MJ, Wong RK. Barrett’s esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:128–135. [PubMed] [Google Scholar]
  • 142.Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol. 2005;3:1–10. doi: 10.1016/s1542-3565(04)00602-0. [DOI] [PubMed] [Google Scholar]
  • 143.Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett’s oesophagus: an overrated risk. Gut. 1989;30:14–18. doi: 10.1136/gut.30.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144.Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249. doi: 10.1093/aje/kwn121. [DOI] [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES